19 results about "Novel protein" patented technology

The present disclosure is generally related to recombinant microbial cells expressing heterologous proteins of interest. Certain aspects of the disclosure are therefore related to, inter alia, recombinant Bacillus cells having enhanced protein production capabilities, novel protein signal sequences, recombinant polynucleotides encoding heterologous proteins of interest, and related compositions and / or methods thereof. Thus, as exemplified herein, the recombinant Bacillus cells of the instant disclosure are particularly suitable for use in the expression, production and secretion of heterologous proteins.

The present disclosure relates generally to recombinant microbial cells expressing heterologous proteins of interest. Accordingly, certain aspects of the present disclosure relate, inter alia, to recombinant Bacillus cells having enhanced protein production capabilities, novel protein signal sequences, recombinant polynucleotides encoding heterologous proteins of interest, and related compositions and / or methods thereof. Thus, as exemplified herein, the recombinant Bacillus cells of the present disclosure are particularly suitable for use in the expression, production, and secretion of heterologous proteins.

The application relates to a protein characterization learning method and device, computer equipment and a storage medium. The method comprises the following steps: collecting protein sequence, structure and function annotation information, and constructing a multi-modal feature data set; performing multi-modal feature extraction on the multi-modal feature data set by using a MASSA framework to obtain protein multi-modal representation; constructing a graph network by using the protein multi-modal representation, and storing the representation and a historical model of an existing protein task in the graph network; in the training process of a new protein task, a memory enhancement mechanism is used to retrieve a similar node of the new protein task from the graph network, a historical model of an existing protein task corresponding to the similar node is obtained, model parameters of the historical model are transferred by using a transfer learning framework, and model training is performed on the new protein task. The application effectively alleviates the data scarcity problem and improves the accuracy and generalization ability of the model in a small sample learning task.

Disclosed are a protein degrader targeting O-GlcNAc Transferase (OGT), and a preparation method therefor and a use thereof. The inventors of the present invention have creatively discovered that a compound recruits MDM2 by means of its interaction with nucleolin (NCL), and through further experiments have found that it can serve as a novel recruiting element for MDM2, which can be used in the preparation of targeted protein degraders and other applications. Using the above findings, the inventors have prepared a novel protein degrader compound targeting OGT, and have found through experimentation that the prepared targeted protein degrader can effectively induce the degradation of OGT, for use in the treatment of diseases mediated by OGT or associated with O-GlcNAc glycosylation (such as neurodegenerative diseases, obesity, tumors, diabetes and complications thereof, cardiovascular diseases, etc.), and will have very promising application prospects in the fields of medicine and health management.

A multimodal generative model of protein families is provided to jointly model the sequences and structures of proteins within a protein family. The model is used for controllable protein generation and representation learning. The model leverages in¬ context learning to infer underlying evolutionary constraints that give rise to the family's characteristic sequence features, structural architectures, and / or functional properties. These inferred evolutionary constraints, coupled with a flexible grammar for specifying explicit sequence and structural constraints, enables the controlled generation of novel family members, including variants with optimized or enhanced characteristics relevant to their function. The model is as an encoder-decoder transformer, preferably one encoder, and two decoders. The encoder processes a user-provided prompt comprising a set of proteins and that guides the two decoders toward generating novel proteins with desired characteristics.

In this invention, the inventors report the characterization of BCLA (brain cyst-loaded antigen), a protein uniquely expressed in the merozoite stage of a parasite. In cysts directly purified from mouse brain, the protein is distributed both internally and on the surface of the cyst. ELISA antibody capture using a combination of serologically reactive BCLA peptide and recombinantly expressed C-terminal domain (rBCLA) constitutes an effective serological marker of latent infection with high sensitivity, definitively and uniquely correlated with the presence of cysts in mouse brain. Antibodies against the BCLA antigen have been detected in human patients. Enrichment titers were detected in patients identified as seropositive for Sag1 or tachyzoite-associated antigen. Further correlation between anti-BCLA IgG synthesis and cysts in humans was demonstrated by significantly stronger recorded titers in the pathology group strongly correlated with the presence of cysts. Furthermore, newborns with confirmed congenital toxoplasmosis showed significantly higher levels of anti-BCLA IgG at birth compared to their mothers, indicating specific intrauterine synthesis of this IgG. Therefore, this invention relates to a novel Toxoplasma gondii protein, hereinafter referred to as BCLA, which is a novel serological marker whose expression is limited to latent toxoplasmosis (schizonts / cysts). This specific protein and its antigenic fragments can be used to detect autoantibodies in patient serum for the diagnosis of latent toxoplasmosis. This invention also relates to derived antibodies that specifically bind to this novel protein, generated through immunization with BCLA.

The present invention relates to novel proteins containing heterodimeric antibody Fc such as bispecific antibodies, and novel methods for preparing such proteins.

This invention discloses a method for retrieving similar protein structures based on hash learning: First, a protein structure dataset is acquired, and the pairwise similarity information is calculated. For the query sample, positive and negative samples are sampled. The protein structures are modeled as a graph, and node and edge features are extracted, the feature representations of nodes and edges are updated, quantization loss and similarity loss are defined, and the final loss function is obtained. The model is then trained. Based on the trained model, each collected protein structure is represented as a binary vector, resulting in a binary vector database. During retrieval, the trained model represents the new protein structure to be retrieved as a binary vector. Similar structures are retrieved by directly calculating the Hamming distance between binary vectors or by constructing an inverted index. Alternatively, the top-ranked protein structures returned based on binary vector retrieval can be reordered using other real-valued vectors or more complex algorithms. This invention reduces storage overhead and improves retrieval speed.

This invention discloses a protein interaction prediction method based on heterogeneous graph neural networks, belonging to the field of protein interaction prediction technology. This invention represents proteins as heterogeneous graphs containing three types of relationships and introduces a relationship modeling mechanism using static weights and learnable scaling parameters. A bimodal contrastive learning framework for sequence pathways and structural pathways is constructed to improve the robustness and generalization of node representations. Furthermore, a relationship-level multi-head adaptive attention mechanism module is designed to adaptively adjust the contribution of different relationships under perceptual conditions. This is a unified framework that can finely express residue-level structural information, maintain controllable model complexity, and enhance generalization ability for novel proteins.

This disclosure relates to a class of peptides derived from Staphylococcus Protein A (SpA) or its domains, which achieve mild elution, such as elution in a pH range of 4.4–6.0, for the efficient separation of immunoglobulins. Methods for separating immunoglobulins using mild elution and related products, such as separation matrices coupled with the peptides or their multimers disclosed herein, are also disclosed.

The technical problem of this invention lies in providing a novel protein cross-linking method. This method promotes the cross-linking reaction by allowing both oxidoreductases such as laccase and protein deamidases such as protein glutaminase to act on the substrate protein.

Traditional research focusing on protein synthesis has focused on the total amount of protein, and therefore requires components that either suppress the decrease in the amount of newly synthesized protein or promote its synthesis. [Solution] Focusing on the synthesis of new proteins, and utilizing a method for evaluating the amount of new protein synthesis in dermal fibroblasts and epidermal keratinocytes, neem leaf extract and kudzu extract are provided as inhibitors of the decrease in the amount of new protein synthesis or as promoters of new protein synthesis.

The present invention belongs to the field of biotechnology, and relates to a phi29 DNA polymerase mutant having a reduced polymerization rate, a preparation method therefore, and a use thereof. The present invention designs mutants of phi29 DNA polymerase, and by means of modifying amino acid residues at at least one of positions 190, 324, 411, 49, 83, 375, 526, 85, 149, 284, 287, 35, 115, 178, 102, 246, 336, 506, 257, 502, 55, 113, 187, 289, 306, 517, 527, 140, 203, 368, 372, 89, 54, 277, 327, 163, and 224 in the amino acid sequence of phi29 DNA polymerase, generates novel proteins that reduce the polymerization rate of the polymerase while maintaining good polymerase activity, successfully solving problems caused by the excessively fast polymerization rate of phi29 DNA polymerase in practical applications, improving the accuracy, stability, and reliability thereof in DNA amplification, sequencing, and other molecular biology experiments, and greatly enhancing sequencing quality.

This invention belongs to the field of phage application technology and discloses a phage lysis protein and its applications. The lysis protein E provided by this invention, as shown in SEQ ID NO.7, is a novel protein, unlike any previously reported phage lysis protein E sequence. The TS protein of this invention exhibits strong lysis ability at position 21, regardless of whether it contains leucine or proline. This discovery breaks with the conventional understanding that proline at position 21 of phage lysis protein E is an essential residue for phage lysis function, providing a new and important theoretical basis for the study of phage lysis of bacteria. It also provides a new theoretical basis and strategic direction for the development of new functional lysis proteins E, and is expected to be applied to the development of new, more powerful phage lysis proteins E for the preparation of drugs or formulations that inhibit pathogenic bacteria.

This application relates to the development and application of a novel protein hair dye. This invention discloses a biological hair dyeing system involving three color proteins, mussel adhesive protein, and split intein, and its application, belonging to the field of biotechnology. This invention uses Escherichia coli as the chassis cell to construct and express a recombinant protein functional module mediated by split intein: three color proteins (red, yellow, and blue) connected to the C-terminus of the split intein, and a mussel adhesive protein connected to the N-terminus of the split intein. The key points of its technical solution include: (1) using red, yellow, and blue primary color proteins to achieve multi-tone and full-spectrum color coverage through precise compounding in different proportions; (2) using the excellent underwater interfacial adhesion ability of mussel adhesive protein to firmly anchor the color-developing module to the surface of hair fibers; (3) using the specific interaction between split inteins and protein trans-splicing reaction to achieve covalent connection between the color-developing module and the adhesive module at the molecular level. This invention effectively overcomes the technical bottlenecks of existing microbial pigments, such as monotonous colors and incomplete color gamut. It has the advantages of rich and controllable color development, mild hair dyeing conditions, excellent color fixing performance, and high biological safety, and has broad application prospects in the field of green cosmetics.

This invention belongs to the field of pharmaceutical technology and discloses the inhibitory effects and mechanisms of action of sclerotinib on lung cancer cells, cervical cancer cells, and ovarian cancer cells. Compared with the currently available broad-spectrum antitumor drug fluorouracil, sclerotinib exhibits superior antitumor properties. In-depth research revealed that sclerotinib acts on the novel protein STAT3 in cancer treatment, inhibiting STAT3 phosphorylation and preventing phosphonate-modified protein dimers from entering the cell nucleus to initiate transcription. Furthermore, sclerotinib inhibits the downstream anti-apoptotic protein BCL-2 of STAT3, synergistically inhibiting tumor cell proliferation. In this study, based on the half-maximal inhibitory concentration (IC50) results of sclerotinib against lung cancer cells A549, cervical cancer cells HeLa, and ovarian cancer cells A2780, we directly verified the anticancer target of sclerotinib through experiments, elucidated its anticancer mechanism, and provided theoretical and experimental basis for its entry into preclinical and clinical trials.

The application discloses a BHET hydrolytic enzyme and application thereof, wherein the amino acid sequence of the BHET hydrolytic enzyme is shown as SEQ ID NO. 1, or has more than 80% homology with the amino acid sequence shown as SEQ ID NO. 1. The nucleotide sequence of the coding gene of the BHET hydrolytic enzyme is shown as SEQ ID NO. 2. The application artificially designs and screens a protein, and obtains a new protein with the function of the BHET hydrolytic enzyme, which can selectively catalyze the conversion of BHET to generate MHET, and is beneficial to realize the directional accumulation of the target intermediate MHET and improve the controllability of the degradation path.

This application relates to compositions and methods for enhanced CNS delivery. In some embodiments, the compositions and methods comprise targeting moieties or molecules, for example, as used in or as a part of engineered AAV capsids, that bind or interact with CBLN1 to mediate delivery of a therapeutic or diagnostic agent throughout the CNS.

De novo protein design, the rational design of new proteins from scratch with specific functions and properties, is a grand challenge in molecular biology. Recently, deep generative models have emerge